Develops radiopharmaceuticals for cancer.
Dec 2025Revenue $90.0K/yrExpenses $36.3M/yr
No trendCash runway ≈ 1.6 years from Jun 2026
Figures by year
When will Actinium Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $90.0K and expenses $36.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $90.0K | $36.3M | −$36.2M |
| Dec 2023 | $81.0K | $52.0M | −$51.9M |
| Dec 2022 | $1.03M | $35.1M | −$34.1M |
| Dec 2021 | $1.14M | $26.1M | −$25.0M |
| Dec 2011 | $0.00 | $3.28M | −$3.28M |
| Dec 2010 | $0.00 | $26.1K | −$26.1K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.